Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-010-1550-3PMID 21181475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study-N05C31.

  2016cited by this paper
• Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.

  2010cited by this paper
• Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients

  2009influential reference
• 2009 ASCO Annual Meeting

  2009cited by this paper
• Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

  2008cited by this paper
• Weekly paclitaxel in the adjuvant treatment of breast cancer.

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

  2008cited by this paper
• Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

  2007cited by this paper
• Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy

  2007cited by this paper
• Vitamin E for prophylaxis against chemotherapy-induced neuropathy

  2005cited by this paper
• Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial

  2005cited by this paper
• Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel

  2004cited by this paper
• Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.

  2003cited by this paper
• [Late phase II study of S-1 in patients with advanced head and neck cancer].

  2001cited by this paper
• Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck An Eastern Cooperative Oncology Group Trial (PA390)

  1999cited by this paper
• Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).

  1999cited by this paper
• Estimates of the worldwide incidence of 25 major cancers in 1990

  1999cited by this paper
• [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].

  1999cited by this paper
• Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.

  1999cited by this paper
• Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck

  1998cited by this paper
• Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.

  1998cited by this paper
• [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].

  1998cited by this paper
• A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies.

  1995cited by this paper
• Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  1994cited by this paper
• Head and Neck Cancer

  1993cited by this paper
• A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

  1992cited by this paper
• Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

  1992cited by this paper
• Head and neck cancer.

  1991cited by this paper
• A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.

  1990cited by this paper
• Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

  1988cited by this paper
• Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate

  1986cited by this paper
• A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer

  1985cited by this paper
• Chemotherapy for head and neck cancer.

  1984cited by this paper
• Promotion of microtubule assembly in vitro by taxol

  1979cited by this paper
• Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

  1971cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer

  2024cites this paper
• A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody

  2024cites this paper
• Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis

  2022cites this paper
• Long-term efficacy of weekly paclitaxel therapy in unresectable primary squamous cell carcinoma of the thyroid.

  2021cites this paper
• Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Clinicopathological study on local recurrence of primary oral squamous cell carcinoma

  2021cites this paper
• Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients

  2021cites this paper
• A case of recurrent oral cancer treated with interchangeable administrations of immune checkpoint inhibitors and chemotherapy agents

  2021cites this paper
• Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab

  2021cites this paper
• Chemotherapy for older patients with head and neck cancer

  2020cites this paper
• Esophageal Cancer

  2020cites this paper
• Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan

  2020cites this paper
• [The Immune Checkpoints Inhibitors for Head and Neck Cancer].

  2019cites this paper
• Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.

  2018cites this paper
• Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

  2018cites this paper
• A case report of refractory metastatic squamous cell carcinoma effectively treated with combination therapy of cetuximab and paclitaxel

  2017cites this paper
• A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.

  2017cites this paper
• Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer

  2017cites this paper
• Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer

  2016cites this paper
• Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer: ―個別化最大継続可能量設定を目的とした開始用量決定のための第1相試験―

  2016cites this paper
• A7RC peptide modified paclitaxel liposomes dually target breast cancer.

  2015cites this paper
• Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

  2015cites this paper
• Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy.

  2015cites this paper
• Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.

  2013cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Review of Clinical Studies

  2012cites this paper
• Chemotherapy-Induced Neuropathic Pain

  2012cites this paper
• Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy

  2012cites this paper
• World Journal of Clinical Oncology

  year unknowninfluential citation